TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21134995
Drug: Hypolipidemic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypolipidemic diet therapy (group Ib, n = 15)
Study: 19034106
Drug: Tariquidar (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tariquidar (150 mg)
Study: 16310974
Drug: Post-treatment motivation
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment motivation
Study: 1590680
Drug: Cefprozil (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefprozil (500 mg every 12 h for 8 days)
Study: 3844036
Drug: Repeated 3-g
Normalized name: glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated 3-g doses of amoxycillin
Study: 3844036
Drug: Single 3-g
Normalized name: glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 3-g dose of amoxycillin
Study: 30706097
Drug: Methylphenidate (MPH,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (MPH, 20 mg)
Study: 30264159
Drug: Loading doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading doses of atorvastatin (80 mg) administered before and 24 hours after PCI.
Study: 30264159
Drug: Loading doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading doses of atorvastatin (80 mg) administered less than 12 hours before PCI.
Study: 30264159
Drug: Loading doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading doses of atorvastatin (80 mg) in patients with ST-segment elevation myocardial infarction (STEMI).
Study: 30264159
Drug: Loading doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading doses of atorvastatin (80 mg) in patients with non-ST-segment elevation ACS.
Study: 23735746
Drug: Golimumab 200
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab 200 mg/100 mg
Study: 23735746
Drug: Golimumab 400
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab 400 mg/200 mg
Study: 23521375
Drug: Single-dose nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose nevirapine (sdNVP)
Study: 18614871
Drug: Combination ZDV/sdNVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ZDV/sdNVP
Study: 18614871
Drug: Short-course highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course highly active antiretroviral therapy (HAART)
Study: 6345428
Drug: Flurbiprofen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (300 mg daily)
Study: 6345428
Drug: Diclofenac (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (200 mg daily)
Study: 30272850
Drug: Individualised nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised nutrition education with customised dishware and food supplements (mixed nuts and skimmed milk powder)
Study: 30272850
Drug: Multiple micronutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrients plus isolated soy protein supplement
Study: 26573239
Drug: Highly filled
Normalized name: Recombinant human highly phosphorylated acid alpha-glucosidase
DrugBank: Recombinant human highly phosphorylated acid alpha-glucosidase (DB17673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly filled flowable composite G-aenial Universal Flo
Study: 25194782
Drug: lithium plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: lithium plus optimal personalized treatment (OPT)
Study: 25194782
Drug: optimal personalized
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: optimal personalized treatment (OPT) alone
Study: 12221218
Drug: Phylloquinone-fortified oil
Normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phylloquinone-fortified oil (377 +/- 46 micro g/d)
Study: 12221218
Drug: Broccoli diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli diet (417 +/- 45 micro g/d)
Study: 10457877
Drug: Continuous spinal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous spinal anaesthesia (1 mL bolus of bupivacaine 0.25% followed by continuous infusion of 10 mL over 24 h)
Study: 10457877
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural anaesthesia (10 mL bolus of bupivacaine 0.25% followed by 2 mL h-1)
Study: 7872388
Drug: Topical aldose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aldose reductase inhibitor (CT-112)
Study: 7872388
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same preparation without the inhibitor)
Study: 6289963
Drug: Ceftriaxone 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 125 mg
Study: 6289963
Drug: Ceftriaxone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (all doses)
Study: 30003336
Drug: Sustained-release β-alanine
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release β-alanine (SR)
Study: 25488303
Drug: Vestipitant (4-36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vestipitant (4-36 mg)
Study: 22101886
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg DHA and 42 mg EPA daily for 3 weeks
Study: 11701404
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin
Study: 17533492
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline plus topical adapalene
Study: 11772906
Drug: Continuous peritoneal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous peritoneal insulin infusion (CPII)
Study: 9694103
Drug: 7.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/kg every 24 hours
Study: 9694103
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg every 8 hours
Study: 8127332
Drug: Betamethasone (5.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (5.7 mg)
Study: 356238
Drug: 900 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/day proquazone
Study: 2670634
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day naproxen
Study: 19416946
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) with oestradiol plus noretisterone acetate
Study: 15226325
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m² plus Paclitaxel 175 mg/m² (AT)
Study: 15226325
Drug: Doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m² plus Cyclophosphamide 600 mg/m² (AC)
Study: 8422345
Drug: Lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (40 mg/day)
Study: 7889227
Drug: Nonparametric rank
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonparametric rank methods (e.g., Wilcoxon rank sum test, Wilcoxon signed rank test)
Study: 7889227
Drug: Extensions for
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extensions for crossover studies comparing more than two treatments
Study: 28546013
Drug: McGrath video
Approvals — FDA: no, EMA: no, PMDA: no
Description: McGrath video laryngoscope group (Group MG)
Study: 28546013
Drug: Head in
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head in the lateral position group (Group L)
Study: 23751136
Drug: Regular prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular prevention efforts supported by national alcohol and drug action plans in control communities
Study: 21596925
Drug: Acetaminophen (4,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4,000 mg/day)
Study: 6465160
Drug: Ibuprofen (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1,200 mg/day)
Study: 17220049
Drug: 0.25% nipradilol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% nipradilol, applied twice daily for 52 weeks
Study: 17220049
Drug: 0.25% nipradilol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% nipradilol, applied twice daily for 8 weeks
Study: 17220049
Drug: 0.5% timolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol, applied twice daily for 8 weeks
Study: 8956759
Drug: soluble L‐selectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: soluble L‐selectin in sera
Study: 8956759
Drug: sVCAM‐1, soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: sVCAM‐1, soluble E‐selectin, and soluble L‐selectin in ELF
Study: 1372660
Drug: Localized hyperthermia
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Localized hyperthermia treatment (43 +/- 0.5C, 6 sessions)
Study: 2951800
Drug: Reproterol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reproterol (1 mg)
Study: 10723150
Drug: Losartan (cozaar,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (cozaar, MSD, USA) 25 mg/day for 48 weeks
Study: 10723150
Drug: Basic medication
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic medication with nitrates, diuretic (on demand), digoxin, and aspirin
Study: 25550339
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2-3 g/day
Study: 25550339
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) 0.06-0.1 mg/kg/day
Study: 9736592
Drug: Moderate-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity warfarin (INR, 2.0 to 2.5) plus aspirin
Study: 9736592
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin (INR, 1.5) plus aspirin
Study: 7520497
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist treatment for three to six months
Study: 26272452
Drug: ropivacaine 0.2
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.2 % + methylprednisolone 1 mg/kg
Study: 26272452
Drug: ropivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine + steroid
Study: 28903941
Drug: Insulin sensitization
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin sensitization (IS) therapy
Study: 16509763
Drug: Immediate-release glipizide
Normalized name: glipizide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release glipizide 5mg (Glynase)
Study: 16509763
Drug: Extended-release glipizide
Normalized name: glipizide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release glipizide 5mg (Glynase) XL
Study: 16509763
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation developed in the laboratory (GLPF)
Study: 16509763
Drug: Extended-release glipizide
Normalized name: glipizide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release glipizide formulations
Study: 15366326
Drug: Inhaled morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled morphine sulfate 2.2 mg
Study: 15366326
Drug: Inhaled morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled morphine sulfate 4.4 mg
Study: 15366326
Drug: Inhaled morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled morphine sulfate 8.8 mg
Study: 15366326
Drug: Inhaled morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled morphine sulfate 17.6 mg
Study: 10904511
Drug: Metformin, 500
Normalized name: Repaglinide-Metformin, 500 mg-1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, 500 mg twice daily (n = 14)
Study: 25857307
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion
Study: 8363025
Drug: Laryngoscopy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laryngoscopy with topical anaesthesia (group 2)
Study: 8363025
Drug: Laryngoscopy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laryngoscopy without topical anaesthesia (group 3)
Study: 19804842
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy
Study: 26401089
Drug: Hybrid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid therapy
Study: 28522130
Drug: Cholecalciferol 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 1,600 IU and calcium carbonate 1,000 mg
Study: 20952244
Drug: Multi-modal treatment
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-modal treatment program (MMT) including heat, Van den Akker manual therapy, stretching, and a return to running program.
Study: 20952244
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (ET) including a home-based ET and a structured return to running program with instruction from a sports physical therapist.
Study: 16535795
Drug: ActivSkin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ActivSkin therapy group
Study: 10764174
Drug: Facemask and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facemask and Oral Airway (FM‐OA)
Study: 29613975
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy for late-onset sepsis
Study: 20461009
Drug: Butyrate enema
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butyrate enema (100 mmol/l butyrate, 60 ml rectal enema, once daily for 2 weeks in healthy volunteers and 3 weeks in UC patients)
Study: 20461009
Drug: Placebo enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo enema (60 ml rectal enema, once daily for 2 weeks in healthy volunteers and 3 weeks in UC patients)
Study: 16123472
Drug: nateglinide/metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: nateglinide/metformin
Study: 16123472
Drug: glyburide/metformin
Normalized name: GLYBURIDE/METFORMIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: glyburide/metformin
Study: 12373613
Drug: Weekly supplementation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supplementation with iron (60 mg as ferrous sulphate) and folic acid (250 micro g) (n=121)
Study: 12373613
Drug: Weekly supplementation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supplementation with vitamin A (2400 RE) in addition to iron and folic acid (n=122)
Study: 12373613
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation group (n=123)
Study: 9599193
Drug: Antilymphocyte antibodies
Normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilymphocyte antibodies (induction therapy)
Study: 3280773
Drug: Prophylactic furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic furosemide (1 mg/kg every 12 hours for four doses beginning at 24 hours of age)
Study: 31895407
Drug: Pembrolizumab therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab therapy (200 mg every 3 weeks for a total of 18 doses)
Study: 31895407
Drug: Pembrolizumab therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab therapy (with irAE)
Study: 31895407
Drug: Pembrolizumab therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab therapy (after onset of irAE)
Study: 30180402
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (20-30 mg/(kg·d))
Study: 30180402
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (3-5 mg/(kg·d))
Study: 26551304
Drug: Clopidogrel +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel + Aspirin (n=84)
Study: 26551304
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Aspirin (n=87)
Study: 23638764
Drug: 22% hydro‐alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22% hydro‐alcohol solution (negative control)
Study: 11966934
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine solution (positive control)
Study: 17367032
Drug: Experimental solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental solution (Cosmocil CQa and Myacide pharma BPa-based)
Study: 17367032
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro (Periogard, Experimental solution, Brushtox, Sterile tap water)
Study: 11303325
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg acetylsalicylic acid (aspirin) daily
Study: 11303325
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg acetylsalicylic acid (aspirin) daily
Study: 11303325
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg and 150 mg acetylsalicylic acid (aspirin) daily
Study: 31183985
Drug: Amorphous solid
Normalized name: Solid
DrugBank: Lactobionic acid (DB16621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorphous solid dispersion formulation
Study: 31183985
Drug: Nanocrystal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocrystal formulation
Study: 22918011
Drug: Butorphanol 1
Normalized name: butorphanol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 1 mg intramuscular
Study: 22918011
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg intramuscular
Study: 31409112
Drug: Clinical trial
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical trial evidence of a 'medication'
Study: 31409112
Drug: Clinical trial
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical trial evidence of a 'topical steroid'
Study: 31409112
Drug: Anecdote of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anecdote of a 'medication'
Study: 31409112
Drug: Anecdote of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anecdote of a 'topical steroid'
Study: 31409112
Drug: Both clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both clinical trial evidence and anecdote of a 'medication'
Study: 31409112
Drug: Both clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both clinical trial evidence and anecdote of a 'topical steroid'
Study: 30801481
Drug: Amifampridine phosphate
Normalized name: Amifampridine Phosphate
DrugBank: Amifampridine (DB11640)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amifampridine phosphate (30-80 mg/d divided into 3 or 4 doses daily)
Study: 26097441
Drug: L-citrulline (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline (0.3 mM)
Study: 26097441
Drug: L-citrulline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline (500 mg/kg/day) + GSH (50 mg/kg/day)
Study: 26097441
Drug: L-citrulline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline (2 g/day) + GSH (200 mg/day)
Study: 26097441
Drug: Cellulose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose placebo (2.52 g/day)
Study: 22401726
Drug: Usual program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual program of the health center (8-10 weekly sessions of 2 hours, no phone calls)
Study: 11499327
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel applied on alternate days for 15 weeks
Study: 11499327
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel applied once daily for 15 weeks
Study: 11499327
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel applied on alternate days
Study: 11499327
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel applied once daily
Study: 8163757
Drug: Intravenous flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous flecainide (2 mg/kg for 10 min and continuous perfusion of 1.5 mg/kg for 1 h)
Study: 8163757
Drug: Intravenous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil (0.15 mg/kg for 5 min and continuous perfusion of 0.005 mg/kg/min for 1 h)
Study: 28154256
Drug: Intrathecal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal dexmedetomidine (5 µg)
Study: 28154256
Drug: Intrathecal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal dexmedetomidine (2.5 µg)
Study: 16388879
Drug: FMP1/AS02A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMP1/AS02A vaccine
Study: 16388879
Drug: Imovax rabies
Normalized name: Imovax Rabies
DrugBank: Rabies virus inactivated antigen, B (DB10062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imovax rabies vaccine
Study: 11812753
Drug: Metformin (2,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2,550 mg/day)
Study: 11812753
Drug: Troglitazone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (600 mg/day)
Study: 12776578
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg once daily)
Study: 27989865
Drug: Mechanical debridement
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical debridement + adjunct antimicrobial photodynamic therapy (MD + aPDT)
Study: 22909270
Drug: Magnesium bisglycinate
Normalized name: Magnesium Bisglycinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium bisglycinate chelate (300 mg per day)
Study: 21906456
Drug: Remifentanil group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil group (propofol at Ce of 6 μg/ml and remifentanil at Ce of 5 ng/ml)
Study: 21906456
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (propofol at Ce of 6 μg/ml and rocuronium 0.8 mg/kg)